The present invention features antibodies that have high binding affinity to human neonatal Fc receptor (FcRn). These anti-FcRn antibodies are useful, e.g., to promote clearance of autoantibodies in a subject, to suppress antigen presentation in a subject, to block an immune response, e.g., block an immune complex-based activation of the immune response in a subject, and to treat immunological diseases (e.g., autoimmune diseases) in a subject.

A modified Ac-TMP-2 protein lacks one or a plurality of acidic C-terminal amino acids normally present in a full-length or wild-type Ac-TMP-2 protein and may also lack one or a plurality of N-terminal amino acids while retaining the amino acid sequence C-S-C at or near the N-terminus. The modified Ac-TMP-2 protein may be useful in method and composition for reducing or alleviating inflammation in a subject. Inflammation may be associated with a disease is a disease of the digestive tract such as chronic gastritis or an inflammatory bowel disease such as Crohn's disease or ulcerative colitis, or a disease of the respiratory system, such as asthma, emphysema, chronic bronchitis, and chronic obstructive pulmonary disease.

Compounds which selectively bind to and inhibit the activity of the potassium channel Kv1.3 are described. Pharmaceutical compositions comprising such compounds and the use of said compounds and said pharmaceutical compositions for the treatment or prevention of autoimmune diseases, obesity, parodontitis and/or tissue transplant rejection are also described.

Provided herein are compounds, compositions, and methods useful for modulating the integrated stress response (ISR) and for treating related diseases; disorders and conditions.

Methods of treating a subject having or at risk of developing a neurodegenerative disease or condition associated with demyelination, insufficient myelination, or underdevelopment of myelin sheath are described. The methods include administration of a therapeutically effective amount of sobetirome, or a pharmaceutically acceptable salt thereof.

The present invention provides a compound of formula (I) or a salt thereof:

##STR00001##

wherein X, L, V, R.sub.1, R.sub.2, R.sub.3 and R.sub.4, are as defined herein.

The present invention provides a compound of formula (I) or a salt thereof:

##STR00001##

wherein X, L, V, R.sub.1, R.sub.2, R.sub.3 and R.sub.4, are as defined herein.

Disclosed herein are recombinant adeno-associated viral vectors expressing 21-hydroxy lase (21OH) protein and related uses for treating 21OH deficiency.

Disclosed herein are recombinant adeno-associated viral vectors expressing 21-hydroxy lase (21OH) protein and related uses for treating 21OH deficiency.

The invention relates to a composite biomaterial based on collagen, on at least one hydrophobic organic polymer and on at least one active ingredient, the process for preparing same, a dressing comprising such a composite biomaterial, an abdominal wall reinforcement comprising such a composite biomaterial, and also the uses of said composite biomateral, especially in the therapeutic field.